RT Journal Article
SR Electronic
T1 Radiation Therapy for Extrapelvic Lymph Node Recurrence After Curative Treatment for Cervical Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 891
OP 895
DO 10.21873/anticanres.13190
VO 39
IS 2
A1 UNO, TAKASHI
A1 KANAZAWA, AKI
A1 NEMOTO, MIHO WATANABE
A1 HARADA, RINTARO
A1 KOBAYASHI, HIROKI
A1 SAITO, MAKOTO
A1 IWAI, YUMA
A1 USUI, HIROKAZU
A1 MITSUHASHI, AKIRA
A1 SHOZU, MAKIO
YR 2019
UL http://ar.iiarjournals.org/content/39/2/891.abstract
AB Background/Aim: To investigate outcomes of patients with cervical cancer who received radiation therapy for extrapelvic lymph node recurrence after initial pelvic radiotherapy. Patients and Methods: The treatment charts of 20 patients were retrospectively reviewed, and factors influencing patient's prognosis were statistically analyzed. Results: The three-year in-field tumor control rate was 55% and overall survival (OS) at 2, 3, and 5 years was 55%, 45%, and 37.5%, respectively. The rate of the three-year OS in patients with recurrence within and after 9 months was 20% and 70%, respectively (p=0.016). None of the 4 patients who were diagnosed with supraclavicular lymph node recurrence alone at more than 9 months after initial treatment experienced further recurrence. Five-year survival of the remaining 16 patients was only 21% (p=0.021). Conclusion: Time to recurrence significantly influenced survival in patients with cervical cancer who received radiotherapy for extra-pelvic lymph node recurrence. Supraclavicular lymph node recurrence alone had a favorable impact on patient's prognosis.